Acumen Pharmaceuticals Inc (ABOS)

Stock Price Forecast

March 22, 2023

Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict

Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Acumen Pharmaceuticals Inc chart...

About the Company

Acumen is a clinical-stage biopharmaceutical company developing a novel disease-modifying approach to target amyloid-beta oligomers, (AβOs), which Acumen believes to be a key underlying cause of Alzheimer’s disease, or AD. Acumen is currently focused on advancing a targeted immunotherapy drug candidate, ACU193, to establish proof of mechanism in early AD patients. Acumen initiated its Phase 1 clinical trial of ACU193 in the second quarter of 2021 with the objective to evaluate its safety and tolerability and explore its pharmacokinetics and target engagement. This trial is currently enrolling patients with mild cognitive impairment and mild dementia due to AD. ACU193 Phase 1 data intended to evaluate safety and tolerability and demonstrate clinical proof of mechanism are expected by year end 2022.





Total Revenue




Market Capitalization


Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $ABOS News

Acumen Pharmaceuticals Inc (ABOS)

2d ago, source: Investing

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all ...

Acumen Pharmaceuticals to Participate in the Needham Neuroscience Forum

13d ago, source: Yahoo Finance

About Acumen Pharmaceuticals, Inc. Acumen, headquartered in Charlottesville, VA, with clinical operations based in Carmel, IN, is a clinical-stage biopharmaceutical company developing a novel ...

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights

1mon ago, source: Yahoo

and CARMEL, Ind., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of novel targeted th ...

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March ...

2d ago, source: Kentucky Today

Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical developing a novel therapeutic that targets toxic soluble amyloid beta oligomers ...

ABOS Acumen Pharmaceuticals, Inc.

6d ago, source: Seeking Alpha

The chart has 1 X axis displaying Time. Data ranges from 2022-03-16 00:00:00 to 2023-03-17 18:18:25. The chart has 1 Y axis displaying values. Data ranges from -50.4 to 68.76.

Acumen Pharmaceuticals To Participate In The Needham Neuroscience Forum

14d ago, source: Mena FN

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 08, 2023 (GLOBE NEWSWIRE) -- acumen pharmaceuticals, inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company ...

Acumen Pharmaceuticals Inc.

4mon ago, source: Barron's

Acumen Pharmaceuticals, Inc. discovers and develops medicines and diagnostics for Alzheimer's disease. The company was founded by William L. Klein, Grant A. Krafft and Caleb Finch in 1996 and is ...

Acumen Pharmaceuticals, Inc. Common Stock (ABOS)

2y ago, source: Nasdaq

Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets. Analysts evaluate the stock’s expected performance in a given time period based on ...

Acumen Pharmaceuticals Inc.

5mon ago, source: Wall Street Journal

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

Acumen Pharmaceuticals Inc (ABOS)

29d ago, source: Investing

Acumen Pharmaceuticals share technical analysis data, signals range from strong buy, buy, neutral, sell to strong Sell. Assess a detailed technical analysis based on the buy/sell signals of moving ...

Latest Neutral (free) Forecasts


Loading the latest forecasts...

My Portfolio

Loading your portfolio...